As we approach June 7, 2023, the evolution of quantum computing is becoming a reality. While this technological advancement has the potential to greatly benefit scientific and industrial applications, it also poses a serious threat to the security of our digital infrastructure, particularly for blockchain-based technologies like cryptocurrencies. The destabilization of this crucial part of our global financial system could have devastating effects.
Despite concerns, quantum computing still has a long way to go before it becomes a viable threat to blockchain technology. However, the inherent security weakness of public keys is the biggest issue for cryptocurrencies as quantum computers continue to grow in power. It is predicted that within the next 5-10 years, a quantum computer running with about 1 million qubits will be able to break keys in a matter of hours. If the current cryptographic hash algorithms ever get cracked, hundreds of billions of dollars worth of digital assets will be left vulnerable to theft from malicious actors.
To counter the threat posed by quantum computing and ensure the security of our future financial transactions and online communications, quantum security standards will inevitably be needed. Developers and entrepreneurs must delve into unexplored territories with respect to cryptographic algorithms and innovate to counter the threat.
However, some experts believe that quantum encryption can combine with blockchains to create protocols that are exponentially more secure than today’s. In theory, these blockchains would be highly resistant to both traditional hacking and quantum computer attacks.
Cambridge Quantum Computing, a startup merging with quantum computer maker Honeywell, is already working on quantum security technology that “can be applied to any blockchain network.” Their aim is to secure both the blockchain and the digital assets that are stored on it.
Updated on: 07/06/2023
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
ARGX Stock Performance: Fluctuations and Future Outlook in Health Technology and Pharmaceuticals Industry
On June 7, 2023, the stock performance of argenx SE (ARGX) opened slightly higher than its previous close at $404.49, but throughout the day’s trading, the stock fluctuated within a range of $399.64 to $408.01. The volume of shares traded was 100,732, which is lower than the average volume of shares traded for the past three months, which was 230,268. Despite the lower trading volume, the market cap of ARGX is still significant at $22.1 billion.
ARGX’s earnings growth last year was -63.59%, but this year, it has seen a positive growth of +51.13%. The company’s projected earnings growth for the next five years is +82.62%, indicating a positive outlook for the future. However, its revenue growth last year was -17.23%, which is a concern for investors.
ARGX’s P/E ratio is not available, but its price/sales ratio is 50.13, which is relatively high. Its price/book ratio is 7.81, which indicates that the stock is slightly overvalued in comparison to its book value.
The next reporting date for ARGX is July 27, 2023, and the EPS forecast for this quarter is -$1.92. The net profit margin for ARGX is -172.76%, which is a significant concern for investors.
ARGX operates in the Health Technology sector and the Pharmaceuticals: Other industry.
ARGX Stock Analysis: Strong Pipeline and Positive Outlook for Investors
ARGX Stock Performances on June 7, 2023: What You Need to Know
ARGX, the biotech company that specializes in developing antibody-based therapies for autoimmune diseases and cancer, has been on the radar of many investors in recent years. With a strong pipeline of products in development and a growing reputation in the industry, the company has been seen as a promising investment opportunity for those looking to capitalize on the growing demand for innovative medical treatments.
On June 7, 2023, ARGX stock was trading at $400.73, with a market capitalization of $23.4 billion. The stock had a 52-week range of $262.50 to $483.68, and was up 0.53% on the day. But what do these numbers really mean for investors, and what can we expect from ARGX in the coming months?
According to data from CNN Money, the 28 analysts offering 12-month price forecasts for argenx SE have a median target of $460.00, with a high estimate of $605.09 and a low estimate of $374.00. The median estimate represents a +14.79% increase from the last price of $400.73. This suggests that analysts are bullish on the future prospects of the company, and believe that it has the potential to generate significant returns for investors.
Furthermore, the current consensus among 29 polled investment analysts is to buy stock in argenx SE. This rating has held steady since May, when it was unchanged from a buy rating. This indicates that analysts remain confident in the long-term prospects of the company, and believe that it is a solid investment opportunity.
Looking at the company’s financials, ARGX reported earnings per share of -$1.92 for the current quarter, with sales of $244.1 million. The company is set to report its earnings on July 27, 2023, and investors will be eagerly awaiting the results to see how the company is performing.
So, what can we expect from ARGX in the coming months? With a strong pipeline of products in development and a growing reputation in the industry, the company is well positioned to capitalize on the growing demand for innovative medical treatments. Furthermore, with analysts bullish on the company’s future prospects and a consensus rating of buy, it seems that many investors are confident in the company’s ability to generate significant returns.
Overall, while there are always risks associated with investing in any company, ARGX appears to be a promising investment opportunity for those looking to capitalize on the growing demand for innovative medical treatments. As always, investors should conduct their own research and due diligence before making any investment decisions.